At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
- Improving Cord Blood Transplantation Outcomes for Adults With High-Risk Blood Cancers
Full Title Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults
Purpose
Umbilical card blood is rich in healthy, blood-forming cells (stem cells) that are very good at fighting blood cancers. Cord blood transplants (CBT) are a standard treatment for adults with blood cancers who lack a genetically matched stem cell donor. Cord blood is donated by a baby’s mother at birth. CBT uses stem cells from cord blood collections to replace cells that have been destroyed by disease or anti-cancer treatment.
Memorial Sloan Kettering Cancer Center (MSK) has developed a standard (“optimized”) practice for CBT using FDA-approved drugs. This optimized practice includes standards for:
- How patients are assessed as candidates for transplant
- The conditioning treatment (standard chemotherapy and total body radiation therapy) used to prepare for transplant
- The amount of stem cells transplanted
- How people are followed during and after CBT
- How patients are monitored for complications after CBT
The purpose of this study is to see if MSK’s optimized CBT practice is safer and more effective. The people in this study have blood cancers with a high risk of returning after treatment, including:
- Acute myeloid leukemia
- Acute lymphoblastic leukemia
- Other acute leukemias
- Myelodysplastic syndromes
- Myeloproliferative disorders
- Non-Hodgkin lymphoma
- Blastic plasmacytoid dendritic cell neoplasm
Who Can Join
To join this study, there are a few conditions. You must:
- Have one of the blood cancers listed above, which has a high chance of coming back after treatment.
- Be recommended for a cord blood transplant.
- Have recovered from the serious side effect of previous therapies.
- Be age 21-65.
Contact
For more information about this study and to see if you can join, please call Dr. Ioannis Politikos’ office at 646-608-3773.
Protocol
23-143Phase
Phase II (phase 2)Disease Status
Relapsed or RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT05884333ClinicalTrials.gov
-
AZD5492 is called a T cell-engaging antibody. AZD5492 helps the immune system target and eliminate cancer cells.
-
Urothelial cancers can grow in different parts of the urinary tract. This includes the ureter (the tube that carries urine from the kidneys to the bladder) and renal pelvis. The renal pelvis is where the ureter connects to the kidneys. The standard treatment is surgery to remove the ureter, kidney, or both. In this study, researchers want to see if enfortumab vedotin, given before surgery, is useful for treating urothelial cancers. The people in this study have high-risk urothelial cancers of the upper urinary tract. High risk means there is a greater chance of the cancer coming back after treatment.
-
Researchers want to see if Tec-RVd after 3 treatment cycles of Dara-RVd is safe for people with multiple myeloma. The people in this study have newly diagnosed multiple myeloma.
-
The standard approach to controlling pain after mastectomy includes intravenous and oral pain-relieving medications. In this study, researchers are determining if adding a long-acting local anesthetic, bupivacaine, into the wound at the end of the operation is more effective at reducing pain than the standard medications alone for women having a mastectomy on one side with no immediate reconstruction afterward.
-
KIF5B/RET is an abnormal gene that leads to the growth of lung cancer cells. Cabozantinib inhibits the effects of this gene. In addition, this drug interferes with other pathways that also cause cancer cells to grow, form new blood vessels, and spread to other parts of the body.
-
Studies have shown that patients with newly diagnosed localized non-germinomatous germ cell tumors (NGGCT) of the brain or spinal cord whose disease responds well to chemotherapy before receiving radiation therapy are more likely to be free of the disease for a longer time than patients in whom chemotherapy is less effective.
-
Researchers are assessing a lower dose of standard radiation therapy after chemotherapy in young people with germinomas. The patients in this study have germinomas of the central nervous system (brain or spinal cord).  It is hoped that this new approach can destroy germinomas with fewer long-term side effects.
-
Researchers in this study are seeking the best dose of CBL0137 in people with solid tumors. They also want to see how well it works against certain cancers.
- A Study of Acupuncture for Young Adults Who Stopped Getting Periods After Chemotherapy
Full Title Acupuncture for Adolescent and Young Adult Cancer Patients: (AcuAYA)
Purpose
Many people who get chemotherapy experience a loss of their period (amenorrhea). They may have menopause-like symptoms such as insomnia, hot flashes, and anxiety. The condition also increases the risk of infertility.
There is no treatment for period loss in people getting chemotherapy for cancer. Researchers are assessing acupuncture to treat amenorrhea caused by chemotherapy in young adults with cancer.
Acupuncture is a medical technique that involves the insertion of very thin needles into specific areas on the body. The goal is to promote health and well-being. Studies have shown that acupuncture may help recover the function of the ovaries and balance sex hormone levels.
If you join this study, you will be randomly assigned to one of these groups:
- The acupuncture group, who will have 12 acupuncture treatments over 12 weeks.
- The control group, who will be put on a waitlist. They will be able to have the same acupuncture treatment as the acupuncture group after a 16-week waiting period.
Who Can Join
To join this study, there are a few conditions. You must:
- Be English-speaking and under age 40.
- Had stage 1, 2, or 3 cancer diagnosed between the ages of 18 and 39.
- Had been having regular periods at the time of your cancer diagnosis.
- Have completed chemotherapy within the past year.
- Have not had a period for at least 3 months after finishing chemotherapy.
Contact
For more information about this study, please contact the Clinical Research Coordinator at [email protected] or 646-449-1074.
Protocol
25-020Phase
Phase II (phase 2)Investigator
Co-Investigators
Xiaotong LiDiseases
Locations
ClinicalTrials.gov ID
NCT06915116ClinicalTrials.gov